Fake COVID-19 vaccinations in Africa

dc.contributor.author	Aborode, A.T.
dc.contributor.author	Awuah, W.A.
dc.contributor.author	Talukder, S.
dc.contributor.author	Oyeyemi, A.A.
dc.contributor.author	Nansubuga, E.P.
dc.contributor.author	Machai, P.
dc.contributor.author	Tillewein, H.
dc.contributor.author	Oko, C.I.
dc.date.accessioned	2022-05-23T07:21:27Z
dc.date.available	2022-05-23T07:21:27Z
dc.date.issued	2022
dc.description.abstract	Deliveries of vaccine supplies by the COVAX programme under the WHO commenced in February 2021.1 COVAX has proposed to distribute 520 million doses to Africa by the end of 2021.1 On 28 March 2021, African Union member states endorsed purchasing 220 million doses of the Johnson & Johnson single shot of the COVID-19 vaccine. However, priority was given to the Johnson & Johnson vaccine to the central-most pooled procurement due to being a single-shot vaccine, being cheap and easy to administer, having good storage conditions and production of doses being within Africa, with fill–finish activities taking place in South Africa.	en_US
dc.identifier.citation	Aborode AT, Awuah WA, Talukder S, et al. Fake COVID-19 vaccinations in Africa. Postgraduate Medical Journal 2022;98:317-318.	en_US
dc.identifier.uri	https://essuir.sumdu.edu.ua/handle/123456789/87786
dc.language.iso	en	en_US
dc.publisher	BMJ	en_US
dc.rights.uri	CC BY-NC 4.0	en_US
dc.subject	COVID-19	en_US
dc.subject	COVAX programme	en_US
dc.subject	Africa	en_US
dc.title	Fake COVID-19 vaccinations in Africa	en_US
dc.type	Article	en_US

Files

Now showing 1 - 1 of 1

Now showing 1 - 1 of 1